Arsanis (NASDAQ:ASNS) posted its quarterly earnings results on Friday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.02), MarketWatch Earnings reports.

Arsanis stock traded down $0.06 during mid-day trading on Friday, hitting $1.37. The company’s stock had a trading volume of 857,225 shares, compared to its average volume of 198,372. The company has a debt-to-equity ratio of 0.20, a quick ratio of 5.54 and a current ratio of 5.54. The firm has a market cap of $19.75 million and a price-to-earnings ratio of -0.08. Arsanis has a twelve month low of $1.25 and a twelve month high of $28.69.

Several research analysts have issued reports on the stock. Piper Jaffray Companies decreased their price target on shares of Arsanis to $2.50 and set a “neutral” rating on the stock in a research report on Monday, August 13th. Zacks Investment Research lowered shares of Arsanis from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. Finally, ValuEngine upgraded shares of Arsanis from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $14.88.

ILLEGAL ACTIVITY WARNING: “Arsanis (ASNS) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at

Arsanis Company Profile

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Read More: Leveraged Buyout (LBO)

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with's FREE daily email newsletter.